Form 15-12G - Securities registration termination [Section 12(g)]
07 November 2024 - 10:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-36818
TRACON Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
124
Washington Street
Foxborough, MA 02035
(508) 543-1720
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the
box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
Rule 12g-4(a)(1) |
|
☒ |
Rule 12g-4(a)(2) |
|
☐ |
Rule 12h-3(b)(1)(i) |
|
☒ |
Rule 12h-3(b)(1)(ii) |
|
☐ |
Rule 15d-6 |
|
☐ |
Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the certification or notice date: Less than 300
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, TRACON Pharmaceuticals, Inc. has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
TRACON PHARMACEUTICALS, INC. |
|
|
|
|
Date: November 7, 2024 |
|
|
|
By: |
|
/s/ Craig R. Jalbert |
|
|
|
|
Name: |
|
Craig R. Jalbert |
|
|
|
|
Title: |
|
President and Chief Executive Officer |
TRACON Pharmaceuticals (QB) (USOTC:TCON)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
TRACON Pharmaceuticals (QB) (USOTC:TCON)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
Echtzeit-Nachrichten über TRACON Pharmaceuticals Inc (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere TRACON Pharmaceuticals Inc (QB) News-Artikel